Today, HIV-positive patients have access to dozens of powerful medications that can keep the virus at bay. Three classes of drugs have emerged in the last five to 10 years as treatment mainstays: non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and integrase inhibitors.
With so many potent medications to choose from, clinicians have embarked on several long-term clinical trials to compare the safety, tolerability and effectiveness of available treatments. Recently, many of these large studies have yielded results that have significantly impacted our understanding of the best first-line treatment.
In a symposium at ICAAC/ICC 2015 in San Diego, University Health Network clinician Sharon Walmsley, M.D., offered her insights on "What to Start With for 2015."